Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models

Size: px
Start display at page:

Download "Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models"

Transcription

1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2001, p Vol. 45, No /01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved. Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models HELGA ERLENDSDOTTIR, 1 JENNY DAHL KNUDSEN, 2 INGA ODENHOLT, 3 OTTO CARS, 3 FRANK ESPERSEN, 2 NIELS FRIMODT-MØLLER, 2 KURT FUURSTED, 2 KARL G. KRISTINSSON, 1 AND SIGURDUR GUDMUNDSSON 4 * Departments of Microbiology 1 and Internal Medicine, 4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden 3 ; and Statens Serum Institut, Copenhagen, Denmark 2 Received 27 January 2000/Returned for modification 14 May 2000/Accepted 23 December 2000 Clinical and animal studies indicate that with optimal dosing, penicillin may still be effective against penicillin-nonsusceptible pneumococci (PNSP). The present study examined whether the same strains of penicillin-susceptible pneumococci (PSP) and PNSP differed in their pharmacodynamic responses to penicillin by using comparable penicillin dosing regimens in four animal models: peritonitis, pneumonia, and thigh infection in mice and tissue cage infection in rabbits. Two multidrug-resistant isolates of Streptococcus pneumoniae type 6B were used, one for which the penicillin MIC was g/ml and the other for which the penicillin MIC was 1.0 g/ml. Two additional strains of PNSP were studied in the rabbit. The animals were treated with five different penicillin regimens resulting in different maximum concentrations of drugs in serum (C max s) and times that the concentrations were greater than the MIC (T >MIC s). The endpoints were bacterial viability counts after 6 h of treatment in the mice and 24 h of treatment in the rabbits. Similar pharmacodynamic effects were observed in all models. In the mouse models bactericidal activity depended on the T >MIC and to a lesser extent on the C max /MIC and the generation time but not on the area under the concentration-time curve (AUC)/MIC. Maximal bactericidal activities were similar for both PSP and PNSP, being the highest in the peritoneum and blood ( 6 log 10 CFU/ml), followed by the thigh ( 3 log 10 CFU/thigh), and being the lowest in the lung ( 1 log 10 CFU/lung). In the rabbit model the maximal effect was 6 log 10 CFU/ml after 24 h. In the mouse models bactericidal activity became marked when T >MIC was >65% of the experimental time and C max was >15 times the and in the rabbit model bactericidal activity became marked when T >MIC was >35%, C max was >5 times the and the AUC at 24 h/mic exceeded 25. By optimization of the C max /MIC ratio and T >MIC, the MIC of penicillin for pneumococci can be used to guide therapy and maximize therapeutic efficacy in nonmeningeal infections caused by PNSP. * Corresponding author. Mailing address: Directorate of Health, Laugavegur 116, IS-101 Reykjavik, Iceland. Phone: Fax: sigurdur@landlaeknir.is. Streptococcus pneumoniae remains one of the leading causes of community-acquired bacterial infections, and severe S. pneumoniae infections such as pneumonia and meningitis have significant morbidity and mortality rates (22). Strains of penicillin-nonsusceptible pneumococci were first reported in 1967 (16) and have spread throughout the world and become prevalent in many countries. The high prevalence of penicillin-nonsusceptible pneumococci has created problems in antimicrobial chemotherapy and has resulted in renewed interest in the management of pneumococcal infections (1, 25, 30). Clinical and animal model studies indicate that by optimizing the dosing of penicillin, it may still be effective against penicillin-nonsusceptible pneumococci (25; V. Magnusson, H. Erlendsdottir, K. G. Kristinsson, and S. Gudmundsson, Program Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A89, p. 17, 1995). Studies in vitro (20; Magnusson et al., 35th ICAAC) and with experimental animals have also demonstrated that the most important pharmacokinetic parameter for establishment of the efficacies of -lactam antibiotics against both penicillin-susceptible and penicillin-nonsusceptible pneumococci is the time that the antibiotic concentration remains above the MIC (T MIC ) (8, 11, 14, 20, 26, 32; A. Thoroddsen, T. Asgeirsson, H. Erlendsdóttir, and S. Gudmundsson, Program Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-5b, p. 27, 1997). Most studies have examined the correlation of pharmacokinetic and pharmacodynamic parameters with efficacy by using experimental models and several bacterial strains with different antimicrobial susceptibilities (20, 32; Thoroddsen et al., 37th ICAAC). This raises the question of the comparability of infections at different sites. Use of the same bacterial strains in several animal models should eliminate the effect of different strain characteristics and thus provide a better understanding of the effects of pharmacokinetic and pharmacodynamic parameters at the different sites of infection (Thoroddsen et al., 37th ICAAC). The purpose of the study described here was to examine whether penicillin-susceptible and penicillin-nonsusceptible pneumococci exhibited different pharmacodynamic responses to penicillin at different sites of infection by using the same pneumococcal strains and comparable penicillin dosing regimens in four animal models: peritonitis, pneumonia, and thigh infection in mice and tissue cage infection in rabbits. (This work was presented in part at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 24 to 27 September 1998 [H. Erlendsdóttir, J. D. Knudsen, I. Odenholt, N. Frimodt-Møller, K. Fuursted, 1078

2 VOL. 45, 2001 PHARMACODYNAMICS IN FOUR ANIMAL MODELS 1079 F. Espersen, O. Cars, K. G. Kristinsson, and S. Gudmundsson, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-2, p. 1, 1998].) MATERIALS AND METHODS Bacteria. For the mouse models, two clinical isolates belonging to a Spanish- Icelandic clone were used (28). One was an isolate (isolate A-2000) from the middle ear of a child with otitis media, and the other was an isolate (isolate R-2151) from the sputum of a patient with pneumonia. Both strains were multidrug-resistant isolates of serotype 6B with similar susceptibility profiles except for susceptibility to penicillin. They were resistant to tetracycline, trimethoprimsulfamethoxazole, and erythromycin. Strain A-2000 was susceptible to penicillin ( g/ml), and strain R-2151 was not susceptible to penicillin ( 1.0 g/ml). For the rabbit model, two clinical penicillin-nonsusceptible isolates were used as well: strain of serotype 6B ( 0.25 g/ml) and strain of serotype 9V ( 2 g/ml). MICs. The MICs were determined by the E test (AB Biodisk, Solna, Sweden), according to the manufacturer s instructions. Animals. Female NMRI mice (age, approximately 6 to 8 weeks; weight, 30 2 g) were used for the mouse pneumonia and the mouse thigh infection models. For the mouse peritonitis model, ssc:cf1 female mice (age, approximately 8 weeks; weight, 30 2 g) were used. Female New Zealand White rabbits (age, 3 to 4 months; weight, 2.5 to 3.2 kg) were used in the tissue cage model. Antibiotic and determination of antibiotic concentrations. Benzylpenicillin was obtained from Astra AB, Södertälje, Sweden, as a dry powder with known potency. Dilutions were made in distilled water. Penicillin concentrations were determined by the disk plate bioassay method (19). For the mouse models the bioassay organism was Micrococcus luteus ATCC 9341 and the growth medium was Mueller-Hinton agar (Difco Laboratories), and for the rabbit model the bioassay organism was Bacillus stearothermophilus ATCC 3032 and the growth medium was tryptose-glucose agar (23). Penicillin was dissolved in pooled normal mouse serum or in 50% rabbit serum for preparation of the standard curves, and the concentrations were derived from the standard curves. The samples were diluted in either pooled normal mouse serum or 50% rabbit serum, so their concentrations would be within the range of those on the standard curve, and the samples were assayed in duplicate. Results were expressed as micrograms per milliliter of fluid. The correlation coefficients of the standard curves were at least 0.99, and the coefficients of variation were below 5%. The lower limit of detection was 0.1 g/ml for the experiments with mice and 0.01 g/ml for the experiments with rabbits. At each dose given, the T MIC s for the different strains were calculated from the serum elimination regression line. The maximum concentration in serum (C max ) in mice was measured 10 min after injection in all mice, and the C max in rabbit serum was measured within 2 h after injection. The serum elimination half-life was estimated by the expression log 2/, where is the slope of the serum elimination regression line (log serum concentration versus time). Protein binding. The level of protein binding of penicillin G in human serum, pooled mouse serum, and rabbit serum was determined by the standard ultrafiltration method (7). The concentrations used for human and mouse serum were 100, 50, 25, 12.5, and 6.25 g/ml, and those used for rabbit serum were 150, 100, and 50 g/ml. The results obtained with the different concentrations were averaged. Animal models. (i) Mouse pneumonia and thigh infection model. Bacterial suspensions were prepared from fresh overnight cultures (made from frozen stock cultures) on 5% blood agar plates. The bacteria were grown in heart infusion broth with 10% horse serum for 6hat35 C to an inoculum of 10 8 CFU/ml. The culture was centrifuged (1,600 g for 20 min) and resuspended in an equal volume of 0.9% saline. The size of the inoculum was determined by viability counting on blood agar plates. The mice were anesthetized by with pentobarbital (50 mg/kg) by intraperitoneal injection. Pulmonary inoculation was performed by nasal installation of 75 l ( CFU) of the bacterial suspension, which was dripped onto the nares of each mouse (Magnusson et al., 35th ICAAC). The mice readily aspirated the solution and were suspended on a string by the upper incisors for 10 to 15 min. Ten hours later the same animals were infected in the thigh by injecting 0.1 ml of 10 6 CFU of the same organism in the logarithmic phase per ml of heart infusion broth with 10% horse serum (15). Antibiotic therapy was initiated 12 h after lung inoculation and 2 h after thigh infection and was continued for 6 h thereafter. The penicillin was administered subcutaneously in the neck region in a volume of 0.2 ml per dose (see Tables 2 and 3). Three mice were in each treatment group, and the experiments were done twice. Inoculated untreated control mice were included in all trials. At the end of the experiment, the animals were killed by cervical dislocation, and the lungs and thighs were removed and homogenized (Omni tissue homogenizer; Omni, Gainesville, Va.) in cold saline with -lactamase (Penase; 100,000 U/ml) to neutralize residual antibiotics. The total volume of lung homogenate was made to 3 ml, and that of the thigh homogenate was made to 10 ml. The bacterial densities in the lungs and thighs were determined by plating serial 10-fold dilutions on blood agar plates (Difco) containing 5 g of gentamicin per ml (17) to prevent growth of contaminating bacteria (the MICs of gentamicin for the test strains were 12 to 24 g/ml). Colony counts were performed after 20 h of incubation at 35 C in 5% CO 2 -supplemented air. The lowest detection levels for the viability counts in the lungs and thighs were 30 and 100 CFU per lung and thigh, respectively. (ii) Mouse peritonitis model. Bacterial suspensions were prepared from fresh overnight cultures (made from frozen stock cultures) on 5% blood agar plates as described above. The inoculum for the mouse peritonitis model was prepared immediately before use by suspending colonies in sterile beef broth medium and was adjusted to an optical density at 540 nm of 0.5, giving a density of approximately 10 8 CFU/ml. The size of the inoculum was determined by viability counting on 5% blood agar. Mucin (M-2378; Sigma Chemical Company, St. Louis, Mo.), an enzyme extract of porcine stomach, was used as an adjuvant for inoculation of the peritoneum (12, 20). Immediately before inoculation, a mucin stock solution (10% [wt/vol]) was diluted 1:1 with the pneumococcal suspension in beef broth (final mucin concentration, 5% [wt/vol]), resulting in an inoculum of to CFU/ml. The mice were injected intraperitoneally with 0.5 ml of the pneumococcal suspension, resulting in bacteremia within 1 h of inoculation (12). Antibiotic therapy was initiated 1 h after inoculation. Penicillin was administered subcutaneously in the neck region in a volume of 0.1 ml per dose (see Tables 2 and 3). Three mice were in each treatment group. Inoculated untreated control mice were included in all trials. The effects of the various treatment regimens were determined after 6 h of treatment by evaluation of bacterial counts in the blood and peritoneal fluid. Blood samples were obtained by periorbital cuts after anesthetization of the mice with CO 2. After the mice were killed, peritoneal washes were performed by injecting 2 ml of sterile saline intraperitoneally, followed by massage of the abdomen and then opening of the peritoneum to collect the fluid. Blood and peritoneal fluids were immediately diluted 10-fold in saline, from which 20 l was plated onto 5% blood agar plates in spots, with subsequent counting of colonies after incubation overnight at 35 C in ambient air. The lowest detection levels for bacterial counts in blood and peritoneal fluid were 50 and 250 CFU/ml, respectively. (iii) Rabbit tissue cage model. The animals were anesthetized by intramuscular injection of 0.5 ml of fentanyl-fluanisone (Hyponorm), followed by disinfection of the back of the rabbits with 70% alcohol and the administration of local anesthesia (lidocaine at 40 mg/ml). A 5-cm incision was then made in the midline, and four well-separated pouches were bluntly dissected in the subcutaneous layer. An autoclaved cylindrical steel-net cage with a volume of 4 ml was implanted in each pouch (23). The incision was closed with sutures. To reverse the anesthesia, the rabbits were given 0.3 to 0.4 ml of naloxone hydrochloride (0.4 mg/ml; Narcante) through an intravenous needle in the ear vein. Three to 4 weeks after the implantation, the tissue cages had sealed with a thin layer of connective tissue and filled with clear, yellowish tissue cage fluid (TCF). Earlier studies have shown that the TCF albumin/serum albumin ratio corresponds very well to the skin albumin/plasma albumin ratio of 0.45 found in humans (3, 23). The bacterial suspensions used in the rabbit tissue cage model were grown in Todd-Hewitt broth for 6hat37 C in 5% CO 2 -supplemented air, resulting in an inoculum of approximate CFU/ml. The four test strains, for which the MICs were different, then in the logarithmic phase of growth, were diluted 10 2 in phosphate-buffered saline (PBS), and thereafter, 0.4 ml of the dilutions was injected into the four different cages, one strain in each cage, giving a starting inoculum in the cages of approximately CFU/ml. Since the C max of penicillin in the tissue cages is reached approximately 1 h after injection, antibiotic therapy was initiated 1 h before inoculation (23). The penicillin was administered by intravenous injection in the ear vein of one dose of 4, 7.5, 15, 75, or 150 mg of penicillin per kg of body weight. Samples from the cages were obtained by percutaneous aspiration every 2nd h up to 12 h and, in addition, after 24 h. Two rabbits were used for each dosing regimen. To avoid antibiotic carryover, the samples were treated with penicillinase (Penase; 100,000 U/ml) and, if necessary, were diluted in PBS before seeding onto blood agar plates. Only plates with 20 to 200 colonies were counted. The lower limit of detection was 20 CFU/ml. Pharmacokinetic studies with mice. Pharmacokinetic studies were done with NMRI mice. Concentrations in sera were determined after the administration of

3 1080 ERLENDSDOTTIR ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. Half-lives, C max s, and T MIC s for the two strains used in the mouse models achieved after administration of a single subcutaneous dose of 1, 10, 50, or 100 mg of penicillin per kg Dose (mg/kg) Half-life (min) C max ( g/ml) T MIC (min) g/ml 1.0 g/ml TABLE 3. C max / T MIC, and T MIC f.d. in mouse serum for both pneumococcal strains achieved with all five regimens a used in the mouse models Regimen C max /MIC T MIC (min [% of treatment period]) T MIC f.d. (min) (12.5) (16) (65) (71) (100) 60 a See Table 2. TABLE 2. Treatment regimens and dosages with time schedules for the penicillin-susceptible (A-2000) and penicillinnonsusceptible (R-2151) pneumococci Time (h:min) Dose (mg/kg) administered to the following mice in the indicated regimen no. a : A-2000 R : : : a The penicillin MIC for strain A-2000 was g/ml; that for strain R-2151 was 1 g/ml. The end point of treatment was 6 h. a single dose of 1, 10, 50, or 100 mg of penicillin per kg. The drug was administered by subcutaneous injection in the neck region in a volume of 0.2 ml per dose. At 10, 20, 40, 60, 90, 120, and 180 min following penicillin administration, blood samples were obtained from the mice in groups of three by periorbital cuts during ether anesthesia. Three to four groups of mice with three mice per group were used, and two to three samples were obtained from each mouse. After collection, the blood was centrifuged and the serum was stored at 80 C until it was analyzed. Pharmacokinetic studies with rabbits. Penicillin concentrations in TCF were determined after the administration of single doses of 4, 7.5, 15, 75, or 150 mg of penicillin per kg. The drug was administered by intravenous injection in the ear vein. Samples from the cages were obtained by percutanous aspiration every 2nd h up to 14 h. TCF pooled from all four cages was used. Two rabbits were used for each dosing regimen. Treatment regimens. The designs of the treatment regimens for the mouse models were based upon the results from the pharmacokinetic studies (see Results) (Table 1). Dosages not included in Table 1 were derived by interpolation. The mice were treated and monitored for 6 h. The treatment regimens and dosages for the animals infected with penicillin-susceptible and penicillin-nonsusceptible organisms are shown in Table 2. The regimens were selected to provide a range of C max s and T MIC s. The range of C max s in serum was 4to100 times the and the range of T MIC s was 45 to 360 min; i.e., the T MIC lasted for 12.5 to 100% of the 6-h experiment (see Table 3). The rabbits were treated with one dose of either 4, 7.5, 15, 75, or 150 mg/kg to provide different T MIC s (0 to 100% of the time during the 24 h after the administration of each dose) for the four different strains used (see the Results and Table 4). Data analysis and presentation. The pharmacokinetic parameters C max, halflives, area under the concentration-time curve (AUC)/ T MIC, and the time that the antibiotic concentration after administration of the first dose (f.d.) of antibiotic remains above the MIC (T MIC f.d. ) were determined from the concentration curves. Total drug concentrations were used in all calculations. The bactericidal efficacies of the treatment regimens in the mouse models were calculated by subtracting the results for each treated mouse from the mean results for control mice at the end of therapy (6 h). In the rabbit model the bactericidal efficacy was determined as the difference between the starting inoculum and the colony count at the end of the experiment at 24 h for all strains. Correlation between pharamacokinetic variables and bactericidal activity was examined by linear regression (Pearson s). The generation time was defined as the time for the viability counts for the untreated organisms in the different mouse models to double. A P value of 0.05 was considered significant. All statistical comparisons were two-tailed. RESULTS Pharmacokinetic studies with mice. Table 1 shows the different half-lives and C max s achieved after the administration of various doses of penicillin and the times that the serum drug levels exceed the MICs for the two strains used in the mouse models. Table 3 demonstrates the C max/mic s and T MIC s for both pneumococcal strains achieved with all five regimens. By univariate analysis, the C max s and T MIC s correlated by a coefficient (r 2 ) of 0.14% (P was not significant). Pharmacokinetic studies with rabbits. Tables 4 and 5 similarly show the different half-lives, T MIC s, and C max s achieved after the administration of five different single-dose regimens. For all the regimens the C max was reached within 2 h. Protein binding. The mean protein binding of penicillin G in human serum was 29.5% (range, 25 to 46%), that in mouse serum was 8.5% (range, 0 to 17%), and that in rabbit serum was 24% (range, 13 to 36%). Bactericidal activity in mouse lungs and thighs. The bactericidal activities of the different treatment regimens in the lungs and thighs are shown in Fig. 1A and 1B. The pharmacodynamic parameters were similar for both the susceptible (Fig. 1A) and the nonsusceptible (Fig. 1B) strains, with maximal bactericidal activities in the thighs of 3.5 and 2.9 log 10 CFU, respectively, and maximal bactericidal activities in the lungs of 1.1 and 0.9 log 10 CFU, respectively. In the thigh model, bactericidal activity became pronounced only when T MIC was TABLE 4. Half-lives and T MIC in the TCF for the four strains used in the rabbit model achieved after the administration of a single intravenous dose of 4, 7.5, 15, 75, or 150 mg of penicillin per kg Dose (mg/kg) Half-life (h) g/ml T MIC (h [% of 24 h]) 0.25 g/ml 1.0 g/ml 2.0 g/ml (100) 28 (100) 20 (83) 16 (67) (100) 20 (83) 14 (58) 12 (50) (100) 13 (54) 3.2 (13) (92) 8.3 (35) 1.4 (5.8) (88) 3.3 (14) 0 0

4 VOL. 45, 2001 PHARMACODYNAMICS IN FOUR ANIMAL MODELS 1081 TABLE 5. C max and C max /MIC in TCF for the four pneumococcal strains achieved with all five regimens in the rabbit model Dose (mg/kg) C max ( g/ml) g/ml C max /MIC 0.25 g/ml 1.0 g/ml 2.0 g/ml , , % of the experimental time or C max was at least 15 times the or both. Similarly, even though the bactericidal activity was very limited in the lungs, it was observed only when T MIC was at least 65% of the experimental time. The correlation of C max, T MIC, T MIC f.d., and AUC/MIC with bactericial activity by univariate analysis is shown in Table 6, and the association with AUC/MIC is demonstrated further in Fig. 2. Bactericidal activity in mouse blood and peritoneum. The bactericidal activity of penicillin in blood and peritoneum is shown in Fig. 3A and B. Pronounced bactericidal efficacy was seen against both blood and peritoneal infections. The pharmacodynamic parameters were similar for both the susceptible (Fig. 3A) and the nonsusceptible (Fig. 3B) strains, with maximal activities in blood of 5.4 and 6.0 log 10 CFU/ml, respectively, and maximal activities in the peritoneum of 5.8 and 6.3 log 10 CFU/ml, respectively. In these infections, bactericidal activity became significant only when T MIC was 65% of the experimental time or C max was at least 15 times the or both. The correlation of C max, T MIC, T MIC f.d., and AUC/MIC with bactericial activity by univariate analysis is shown in Table 6, and the association with AUC/MIC is demonstrated further in Fig. 2. Bactericidal activity in rabbit TCF. As shown in Table 4, the concentration of penicillin in the cages after the administration of a dose of 15 mg/kg never exceeds the MICs for strain ( 2.0 g/ml). As an example, Fig. 4 shows the different bactericidal activity curves for the four test strains following the administration of a penicillin dose of 15 mg/kg. For the strain for which the MIC was 1.0 g/ml, the T MIC after this dose was 3.2 h (13% of the 24-h experiment), but the C max / MIC was only 1.6 and there was no bactericidal activity against the two nonsusceptible strains. For the intermediate ( 0.25 g/ml), the 15-mg/kg dose provided a T MIC of 13 h (54%) and the C max /MIC was 6.3. For the sensitive strain, the T MIC was 32 h (100%) and the C max /MIC was 99. Significant bactericidal activity was achieved only against these two strains (MICs, and 0.25 g/ml, respectively). The bactericidal activities of all five regimens against the four test strains are shown in Fig. 5 as a correlate of the respective T MIC s, C max /MICs, and AUC/MICs 24 h after dosing. Maximal bactericidal activity was obtained when the T MIC was at least 35% of the experimental time, C max exceeded 5 times the and AUC/MIC exceeded 25. Generation times. Maximum bactericidal activity was associated with the generation times of the untreated control organisms in the different mouse models, as demonstrated in Fig. 6(r ; P 0.01). The generation time in the lungs was long, approaching infinity, and strain R-2151 ( 1.0 g/ml) had a 1.3- to 3-fold longer generation time than strain A-2000 ( g/ml). DISCUSSION The major aim of the present study was to evaluate the bactericidal activity of penicillin against penicillin-susceptible FIG. 1. Bactericidal activities of five treatment regimens in mouse lungs and thighs. (A) Susceptible strain A-2000; (B) nonsusceptible strain R Results are given for each regimen as log 10 CFU reduction between control mice and treated mice at 6 h. The bars show the means and standard deviations for six mice. Below the x axis the multiples of the MIC (C max /MIC) and the T MIC as a percentage of the 6-h experiment for each regimen are provided.

5 1082 ERLENDSDOTTIR ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 6. Correlation (by univariate analysis) of bactericidal activity with C max, T MIC, T MIC f.d., and AUC/MIC in the mouse infection models for two type 6B pneumococcal isolates, A-2000 and R-2151 a Mouse model Parameter r 2 for A-2000 P for A-2000 r 2 for R-2151 P for R-2151 Thigh C max T MIC T MIC f.d AUC/MIC Lung C max T MIC T MIC f.d AUC/MIC Peritoneum C max T MIC T MIC f.d AUC/MIC Blood C max T MIC T MIC f.d AUC/MIC a The penicillin MIC for strain A-2000 was g/ml; that for strain R-2151 was 1.0 g/ml. Statistically significant values are boldfaced. and penicillin-nonsusceptible pneumococcal strains in four different animal models. Previous studies with experimental animals (2, 13, 29; Magnusson et al., 35th ICAAC) and limited studies with humans (25) have shown that penicillin-nonsusceptible pneumococci can be treated with penicillin. The experimental studies were performed with single animal models. The current study is the first that has examined these issues concurrently in different animal models at different sites of infection but with the same organisms and the same antimicrobial agent at comparable dosages. Furthermore, the end points in this study were not survival but bactericidal activity as determined by the viable counts in all models. Since the halflife in the rabbit model was 2.9 to 4.4 h but was only 12.1 to 16.1 min in mice, the end point of therapy in the tissue cages was chosen to be 24 h after dosing of the drug, but in the mouse models the end point was chosen to be 6 h after the initiation of therapy. The main findings of this study are as follows. (i) Similar pharmacodynamic patterns were observed in all models, although bactericidal activity was lowest in the lung. (ii) The bactericidal effect of penicillin in all models against both the penicillin-susceptible and penicillin-nonsusceptible pneumococci was dependent on both T MIC and, to a lesser extent, C max, but it was not dependent on AUC/MIC. (iii) The bactericidal activity in the mouse models correlated with the in vivo generation time. The virulence of pneumococci in mice varies with capsular type. Penicillin-nonsusceptible pneumococci are dominated by capsular types with low levels of virulence for mice, i.e., types 6B, 14, 19, and 23 (4). In the present study pneumococcal strains of serotype 6B were used in all models, and in addition, one strain of serotype 9V was used in the tissue cage model. The serotype 6B strains were multidrug resistant and exhibited similar levels of resistance to most antibiotics tested except penicillin, which had MICs from to 1.0 g/ml. The studies were done with immunocompetent mice. Previous data (21; H. Erlendsdóttir, S. Ómarsdóttir, V. Magnússon, and S. Gudmundsson, Program Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-5c, p. 27; 1997) have indicated that pharmacokinetic parameters in infected and uninfected mice are comparable. It has previously been shown with experimental animal models that the most important pharmacokinetic parameter for prediction of the effects of -lactam antibiotics in vivo against penicillin-susceptible pneumococci is T MIC (8, 11, 20, 32). An earlier study examined the efficacy of penicillin in 100 different penicillin dosing regimens against a penicillin-sensitive pneumococcus ( g/ml) in the mouse thigh model (32). Therapeutic efficacy was achieved when levels in serum were constantly maintained above the MIC. In the present study, the pharmacokinetic datum points did not allow the complete sep- FIG. 2. Association of bactericidal activity of five different regimens with AUC/MIC at four different infection sites in mice. (A) Results for susceptible strain A (B) Results for nonsusceptible strain R-2151.

6 VOL. 45, 2001 PHARMACODYNAMICS IN FOUR ANIMAL MODELS 1083 FIG. 3. Bactericidal activities of five different treatment regimens in mouse peritoneum and blood. (A) Results for susceptible strain A (B) Results for nonsusceptible strain R Results are given for each regimen as log 10 CFU reduction between control mice and treated mice at 6 h. The bars show the means and standard deviations for three mice. Below the x axis the multiples of the MIC (C max /MIC) and the T MIC as a percentage of the 6-h experiment for each regimen are provided. aration of the interdependence between T MIC and C max, but it was not the primary goal. Nevertheless, the correlation between the two parameters was poor by univariate analysis (r 2 14%). Furthermore, the correlations of the bactericidal activity with T MIC were higher (r 2 54 to 94%) in all mouse models for both isolates than the correlations with C max (r to 49%) and AUC/MIC (r 2 14 to 75%) except for those for the nonsusceptible isolate in the lung (for T MIC, r 2 37%; for C max, r 2 79%; for AUC/ r 2 97%). Thus, the results in the present study achieved with the same isolates at several different infection sites are consistent with those of previous single-infection-site studies (8, 11, 20, 31). In the present study the T MIC after administration of the first dose of antibiotic did not correlate with the bactericidal activity at the end of treatment except for that against the nonsusceptible isolate in the lung (P 0.019). It should be noted, however, that a certain maximum-effect threshold for C max, T MIC, and T MIC f.d. can be deducted from the results from studies with mice (Fig. 1 and 3). Only a few studies have investigated whether the same pharmacodynamic parameters apply to penicillin-susceptible and penicillin-nonsusceptible pneumococci, but in the present studies there have been indications that penicillin at the appropriate dosages can be used to treat infections caused by penicillin-nonsusceptible pneumococci. Azoulay-Dupuis et al. (2) showed in a leukopenic mouse pneumonia model that the dose of amoxicillin (50 mg/kg) required to protect mice and to eradicate penicillin-nonsusceptible strains was 10 times higher than the dose which was effective against penicillin-susceptible strains. Tateda et al. (29) showed that the ratio of the penicillin MICs for the two pneumococcal strains tested (1.0/0.015 g/ ml) was the same as the ratio of the two penicillin dosages (40/0.6 mg/kg) required to clear the pneumonia from immunocompetent mice. The doses were given six times at 1-h intervals. These results are consistent with those of Knudsen et al. (20), who showed a highly significant correlation between the log MIC and the log 50% effective dose in a mouse peritonitis model. Moreover, earlier Magnusson et al. (35th ICAAC) showed that high penicillin dosages of up to 200 mg/kg/24 h, with doses given every 1 or every 3 h, were efficacious in the treatment of pneumonia due to penicillin-nonsusceptible FIG. 4. Killing and growth curves for the four pneumococcal strains (MICs, 0.016, 0.25, 1, and 2 g/ml, respectively) for 24 h in the rabbit tissue cages following the intravenous administration of 15 mg of penicillin per kg. The curves show the mean number of CFU per milliliter for two rabbits at each time point.

7 1084 ERLENDSDOTTIR ET AL. ANTIMICROB. AGENTS CHEMOTHER. nonsusceptibility was not associated with increased mortality in a series of 208 children with pneumococcal bacteremia without infection in the central nervous system. Einarsson et al. (9) found in a recent case control study that patients with pneumonia due to penicillin-nonsusceptible strains presented with a milder illness than patients infected with susceptible strains but had prolonged hospital stays and required more expensive antibiotics. These results might be explained by the fact that penicillin resistance is more common among serotypes with lower levels of virulence (18). In the present study the bactericidal activity in lungs was limited, the reason for which is not entirely clear, but the long generation time in the lungs is probably the most important factor. Several investigators have previously reported a significant association between the generation time in untreated organisms and the bactericidal activities of -lactams, for example, for Escherichia coli (31) and group A beta-hemolytic streptococci (24). In a previous study (Thoroddsen et al., 37th ICAAC) of pneumococcal serotype 6B infection in the lungs and thighs in healthy and neutropenic mice, the bactericidal activity of penicillin was monitored at regular intervals for 24 h after the administration of one 100-mg/kg dose of penicillin. The maximal bactericidal effect was reached 4 to 12 hours later in the lungs than in the thighs. The antibiotic concentration at the infection site does not explain this difference, because values for the most important parameter for establishment of the effect of -lactams, T MIC, were similar at both sites (Erlendsdóttir et al., 37th ICAAC). Thus, the bactericidal activity in the lungs in the present study may have been more pronounced if it had been monitored for a longer period, but the studies were done with immunocompetent mice, which limited the experimental time. The antibiotic concentration at the infection site is also important. In rabbits it has been shown that the concentrations of -lactams in muscle interstitial fluid closely approximate those observed in serum, with only a short lag time (5, 27). Similarly, comparison of the pharmacokinetics of penicillin in mouse serum and lungs (Erlendsdóttir et al., 37th ICAAC) has shown good penetration of penicillin into murine lung tissue. However, C max was much higher in serum than in lungs, with a FIG. 5. Bactericidal activities of all five regimens (4, 7.5, 15, 75, and 100 mg/kg) against the four test strains in the rabbit tissue cages as a function of the respective T MIC s (A) C max /MIC (B), and AUC/MIC (C) 24 h after dosing. pneumococci in mice. That study also indicated that a certain threshold penicillin C max of approximately 6 g/ml was necessary for in vivo efficacy. However, beyond this, an increased dosage did not improve the bactericidal activity further. This was seen with both the penicillin-susceptible and the penicillinnonsusceptible strains tested and also in the in vitro experiments with the same strains. Few studies with humans have obtained results consistent with these findings. Pallares et al. (25) reported that penicillin resistance is not associated with an increased rate of mortality in patients with bacteremic pneumococcal infections that were treated with penicillin. Friedland (10) showed that penicillin FIG. 6. Correlation between generation time of the untreated control organisms in the different mouse models and maximum bactericidal activity. The generation time in the lungs approached infinity, but the duration was arbitrarily chosen as 1,000 min.

8 VOL. 45, 2001 PHARMACODYNAMICS IN FOUR ANIMAL MODELS 1085 ratio of 2/1 to 3/1. In contrast, the half-lives were considerably longer in lungs than in serum (20%), resulting in comparable T MIC s. However, in the tissue cage, due to a large volumeto-surface area ratio, an even antibiotic concentration at the infection site is achieved during the induction phase (23). The -lactams accumulated slowly in TCF, and the C max in TCF was lower than that in serum, but the half-life was much longer. For instance, a single intravenous injection of ampicillin (20 mg/kg) to rabbits resulted in a half-life of 28 min in serum and one of approximately 2.5 h in TCF (6). In the present study the half-life of penicillin in TCF ranged from 2.9 to 4.9 h. Therefore, levels in serum were used as surrogate markers for the concentration at the infection sites in the mouse models, while the concentrations in TCF were used as surrogate markers in the rabbit model. The question arises as to whether infection alters the pharmacokinetic parameters. It has been shown that the pharmacokinetic parameters for penicillin 18 to 22 h after infection were the same in both serum and lungs in infected and uninfected mice (Erlendsdóttir et al., 37th ICAAC). By the same token, peritonitis does not alter the parameters at the start of the infection (21). In summary, the present study showed that the pharmacokinetic parameters associated with the efficacy of penicillin against pneumococci with different susceptibilities were remarkably similar in the four animal models and nearly identical at the different sites of infection in the mice. Thus, in conclusion, the MIC of penicillin for pneumococci can be used to adjust the dosage required to achieve an optimum outcome with penicillin treatment regimens when one is treating nonmeningeal infections. ACKNOWLEDGMENT This work was supported by a Scandinavian Society of Chemotherapy research grant for research in antimicrobial chemotherapy. REFERENCES 1. Appelbaum, P. C Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15: Azoulay-Dupuis, E., P. Moine, J. P. Bedos, V. Rieux, and E. Vallee Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob. Agents Chemother. 40: Bergholm, A. M., C. Henning, and S. E. Holm Static and dynamic properties of tissue cage fluids in rabbits. Eur. J. Clin. Microbiol. 3: Briles, D. E., M. J. Crain, B. M. Gray, C. Forman, and J. Yother Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect. Immun. 60: Cars, O Tissue distribution of ampicillin: assay in muscle tissue and subcutaneous tissue cage fluid from normal and nephrectomized rabbits. Scand. J. Infect. Dis. 13: Cars, O., C. Henning, and S. E. Holm Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: relation to serum and tissue protein binding. Scand. J. Infect. Dis. 13: Craig, W. A., and B. Suh Protein binding and antimicrobial effects: methods for determination of protein binding, p In V. Lorian (ed.), Antibiotics in labaratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, Md. 8. Drusano, G. L., and F. W. Goldstein Relevance of the Alexander Project: pharmacodynamic considerations. J. Antimicrob. Chemother. 38 (Suppl. A): Einarsson, S., M. Kristjansson, K. G. Kristinsson, G. Kjartansson, and S. Jonsson Pneumonia caused by penicillin non-susceptible and penicillin susceptible pneumococci in adults: a case-control study. Scand. J. Infect. Dis. 30: Friedland, I. R Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr. Infect. Dis. J. 14: Frimodt-Møller, N., M. W. Bentzon, and V. F. Thomsen Experimental pneumococcus infection in mice: comparative in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J. Infect. Dis. 154: Frimodt-Møller, N., J. D. Knudsen, and F. Espersen The mouse peritonitis/sepsis model, p In O. Zak et al. (ed.), Handbook of animal models of infection. Academic Press, Inc., New York, N.Y. 13. Gavalda, J., J. A. Capdevila, B. Almirante, J. Otero, I. Ruiz, M. Laguarda, H. Allende, E. Crespo, C. Pigrau, and A. Pahissa Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats. Antimicrob. Agents Chemother. 41: Gerber, A. U Impact of the antibiotic dosages schedule on efficacy in experimental soft tissue infections. Scand. J. Infect. Dis. Suppl. 74: Gudmundsson, S., and H. Erlendsdottir Murine thigh infection model, p In O. Zak et al. (ed.), Handbook of animal models of infection. Academic Press, Inc., New York, N.Y. 16. Hansman, D., and M. M. Bullen A resistant pneumococcus. Lancet ii: Hendley, J. O Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J. Infect. Dis. 132: Kaplan, S. L., and E. O. Mason Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11: Klassen, M., and S. C. Edberg Measurement of antibiotics in human body fluids: techniques and significance, p In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md. 20. Knudsen, J. D., N. Frimodt-Møller, and F. Espersen Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob. Agents Chemother. 39: Knudsen, J. D., N. Frimodt-Møller, and F. Espersen Pharmacodynamics of penicillin are unaffected by bacterial growth phases of Streptococcus pneumoniae in the mouse peritonitis model. J. Antimicrob. Chemother. 41: Mufson, M. A Streptococcus pneumoniae, p In G. L. Mandell, R. G. Douglas, and J. E. Bennet (ed.), Principles and practice of infectious diseases, 3rd ed. Churchill Livingstone Inc., New York, N.Y. 23. Odenholt, I., S. E. Holm, and O. Cars An in vivo model for evaluation of the postantibiotic effect. Scand. J. Infect. Dis. 20: Odenholt, I Pharmacodynamics of -lactam antibiotics, p. 29. Ph.D. thesis. Akademitryk, Uppsala, Sweden. 25. Pallares, R., J. Linares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333: Roosendaal, R., and I. A. J. M Bakker-Woudenberg Impact of the antibiotic dosage schedule on efficacy in experimental lung infections. Scand. J. Infect. Dis. Suppl. 74: Ryan, M., and O. Cars Antibiotic assays in muscle: are conventional tissue levels misleading as indicator of the antibacterial activity? Scand. J. Infect. Dis. 12: Soares, S., K. G. Kristinsson, J. M. Muser, and A. Tomasz Evidence for introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980 s. J. Infect. Dis. 168: Tateda, K., K. Takashima, H. Miyazaki, T. Matsumoto, T. Hatori, and K. Yamaguchi Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob. Agents Chemother. 40: Tomasz, A Pneumococcus at the gates. N. Engl. J. Med. 333: Tuomanen, E., R. Cozens, W. Tosch, O. Zak, and A. Tomasz The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J. Gen. Microbiol. 132: Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:

Received 23 December 1996/Returned for Modification 26 April 1997/Accepted 30 June 1997

Received 23 December 1996/Returned for Modification 26 April 1997/Accepted 30 June 1997 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1997, p. 1910 1915 Vol. 41, No. 9 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Activities of Vancomycin and Teicoplanin against Penicillin-Resistant

More information

Animal models for the study of. staphylococci. Niels Frimodt Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital Denmark

Animal models for the study of. staphylococci. Niels Frimodt Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital Denmark Animal models for the study of antibiotic PKPD against staphylococci Niels Frimodt Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital Denmark Animal models for antibiotic acitivity

More information

In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model

In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2009, p. 3003 3009 Vol. 53, No. 7 0066-4804/09/$08.00 0 doi:10.1128/aac.01584-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. In Vivo

More information

Postantibiotic and Sub-MIC Effects of Azithromycin and Isepamicin against Staphylococcus aureus and Escherichia coli

Postantibiotic and Sub-MIC Effects of Azithromycin and Isepamicin against Staphylococcus aureus and Escherichia coli ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1998, p. 414 418 Vol. 42, No. 2 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Postantibiotic and Sub-MIC Effects of and against Staphylococcus

More information

Pharmacodynamics of a New Streptogramin, XRP 2868, in Murine Thigh and Lung Infection Models

Pharmacodynamics of a New Streptogramin, XRP 2868, in Murine Thigh and Lung Infection Models ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2006, p. 243 249 Vol. 50, No. 1 0066-4804/06/$08.00 0 doi:10.1128/aac.50.1.243 249.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.

More information

ABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18

ABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18 M26-A ISBN 1-56238-384-1 September 1999 ISSN 0273-3099 Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline Volume 19 Number 18 Arthur L. Barry, Ph.D. William A. Craig,

More information

Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Drivers of Iclaprim

Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Drivers of Iclaprim AAC Accepted Manuscript Posted Online 29 January 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.02550-17 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 Identification of the

More information

In Vivo Pharmacodynamics of New Lipopeptide MX-2401

In Vivo Pharmacodynamics of New Lipopeptide MX-2401 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2010, p. 5092 5098 Vol. 54, No. 12 0066-4804/10/$12.00 doi:10.1128/aac.00238-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. In Vivo

More information

Johan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands

Johan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Can pk/pd replace clinical trials? Johan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands The Traditional Approach Phase Participants Research questions Number Characteristics I 10-50 Usually

More information

In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 943 949 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vivo Pharmacodynamic Activities

More information

Pharmacodynamics of Ampicillin-Sulbactam in an In Vitro Infection Model against Escherichia coli Strains with Various Levels of Resistance

Pharmacodynamics of Ampicillin-Sulbactam in an In Vitro Infection Model against Escherichia coli Strains with Various Levels of Resistance ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1998, p. 231 235 Vol. 42, No. 2 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Pharmacodynamics of Ampicillin-Sulbactam in an In Vitro

More information

obtained from the infected and treated tissues, Fleming's2 technic of hemolytic streptococcus B. Immediately following the infection, 1.0 ml.

obtained from the infected and treated tissues, Fleming's2 technic of hemolytic streptococcus B. Immediately following the infection, 1.0 ml. THE SENSITIVITY OF STREPTOCOCCI TO PENICILLIN G AFTER EXPOSURE TO THE ANTIBIOTIC IN VIVO* E. GRUNBERG, C. UNGER, AND D. ELDRIDGE Previous investigations by Grunberg, Schnitzer, and Unger3 on the topical

More information

Rate of Penicillin Killing of Staphylococcus aureus and

Rate of Penicillin Killing of Staphylococcus aureus and JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 1982, p. 27-274 95-1137/82/227-5$2./ Vol. 15, No. 2 Rate of Penicillin Killing of Staphylococcus aureus and Autobac 1 Susceptibility Test Results JO-ANN HARRIS' AND

More information

Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice

Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice Journal of Antimicrobial Chemotherapy Advance Access published March 16, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq072 Novel polymyxin derivatives are effective in treating experimental Escherichia

More information

Factors Influencing Detection of Tolerance in Staphylococcus aureus

Factors Influencing Detection of Tolerance in Staphylococcus aureus ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1982, p. 364-368 Vol. 22, No. 3 0066-4804/82/090364-0$02.00/0 Copyright 1982, American Society for Microbiology Factors Influencing Detection of Tolerance in

More information

Determination of Penicillin MICs for Streptococcus pneumoniae by Using a Two- or Three-Disk Diffusion Procedure

Determination of Penicillin MICs for Streptococcus pneumoniae by Using a Two- or Three-Disk Diffusion Procedure JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 179 183 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology Determination of Penicillin MICs for Streptococcus pneumoniae

More information

SKIN INFECTION OF RABBITS WITH HEMOLYTIC STREP- TOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS.

SKIN INFECTION OF RABBITS WITH HEMOLYTIC STREP- TOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS. SKIN INFECTION OF RABBITS WITH HEMOLYTIC STREP- TOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS. I. METHOD OF DEMONSTRATING PROTECTIVE ACTION OF IMMUNE SERA. BY THOMAS M. RIVERS, M.D. (From the Hospital

More information

Setting Clinical Breakpoints/ECOFFS

Setting Clinical Breakpoints/ECOFFS 23 rd August 2016 Setting Clinical Breakpoints/ECOFFS Robin A Howe Antimicrobial use in Primary Care An E. coli is grown from blood cultures Cefuroxime MIC 2mg/L Zone around CXM 30ug disc 27mm Is it sensitive?

More information

Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo

Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1999, p. 2473 2478 Vol. 43, No. 10 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Use of Pharmacodynamic Indices

More information

In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium

In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium ORIGINAL ARTICLE In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium I. Odenholt, E. LoÈwdin and O. Cars Antibiotic

More information

Biofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement

Biofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement Biofilm Protocol Optimization For Pseudomonas aeruginosa Culture Media, Incubation Time, and Biofilm Measurement Introduction In addition to the conventional arsenal of antibiotic resistance mechanisms

More information

Determination of MIC & MBC

Determination of MIC & MBC 1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight

More information

Determination of MIC & MBC

Determination of MIC & MBC 1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight

More information

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide Journal of Antimicrobial Chemotherapy (2005) 55, Suppl. S2, ii25 ii30 doi:10.1093/jac/dki008 JAC Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

More information

Transmission Electron Microscopic Study of Antibiotic Action on Klebsiella pneumoniae Biofilm

Transmission Electron Microscopic Study of Antibiotic Action on Klebsiella pneumoniae Biofilm ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2002, p. 2679 2683 Vol. 46, No. 8 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.8.2679 2683.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.

More information

Postantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae

Postantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae Journal of Antimicrobial Chemotherapy (1987) 20, Suppl. B, 39-46 Postantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae

More information

Pharmacokinetics as applied to in vitro and animal models

Pharmacokinetics as applied to in vitro and animal models Pharmacokinetics as applied to in vitro and animal models Michael R. Jacobs, MD, PhD Case Western Reserve University University Hospitals of Cleveland Cleveland, OH Topics In vitro pharmacodynamic models

More information

Pharmacokinetic and Pharmacodynamic Models of the Antistaphylococcal Effects of Meropenem and Cloxacillin In Vitro and in Experimental Infection

Pharmacokinetic and Pharmacodynamic Models of the Antistaphylococcal Effects of Meropenem and Cloxacillin In Vitro and in Experimental Infection ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1997, p. 2083 2088 Vol. 41, No. 10 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Pharmacokinetic and Pharmacodynamic Models of the

More information

PK-PD TARGET SELECTION It s All About the Goal

PK-PD TARGET SELECTION It s All About the Goal PK-PD TARGET SELECTION It s All About the Goal Paul G. Ambrose, Pharm.D. Chair, USCAST Executive Committee President, Institute for Clinical Pharmacodynamics It s All About the Goal The choice of a rational

More information

Concentration Effect Relationship of Ceftazidime Explains Why The Static Effect In Vivo Is 40% ft>mic. ACCEPTED

Concentration Effect Relationship of Ceftazidime Explains Why The Static Effect In Vivo Is 40% ft>mic. ACCEPTED AAC Accepts, published online ahead of print on 18 June 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01586-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

FURTHER OBSERVATIONS ON THE AGGLUTINATION OF BACTERIA IN VIVO.

FURTHER OBSERVATIONS ON THE AGGLUTINATION OF BACTERIA IN VIVO. FURTHER OBSERVATIONS ON THE AGGLUTINATION OF BACTERIA IN VIVO. BY CARROLL G. BULL, M.D. (From the Laboratories of The Rockefeller Institute for Medical Research.) PLATE 7. (Received for publication, April

More information

DETERMINATION OF THE ID50 VALUES OF ANTIBACTERIAL AGENTS IN AGAR. TAKAKO KATO, SATONORI KURASHIGE, Y. A. CHABBERT* and SUSUMU MITSUHASHI

DETERMINATION OF THE ID50 VALUES OF ANTIBACTERIAL AGENTS IN AGAR. TAKAKO KATO, SATONORI KURASHIGE, Y. A. CHABBERT* and SUSUMU MITSUHASHI 1299 DETERMINATION OF THE ID50 VALUES OF ANTIBACTERIAL AGENTS IN AGAR TAKAKO KATO, SATONORI KURASHIGE, Y. A. CHABBERT* and SUSUMU MITSUHASHI Department of Microbiology, School of Medicine, Gunma University,

More information

Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces

Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces Test Organisms: Staphylococcus aureus (ATCC 6538) Enterobacter aerogenes (ATCC 13048) Pseudomonas aeruginosa

More information

Optimal Times above MICs of Ceftibuten and Cefaclor in

Optimal Times above MICs of Ceftibuten and Cefaclor in ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 14, p. 1112-111 Vol. 3, No. 5 0066-404/4/$04.00 + 0 Optimal Times above MICs of Ceftibuten and Cefaclor in Experimental Intra-Abdominal Infections CYPRIAN 0.

More information

Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group

Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group Journal of Antimicrobial Chemotherapy (99) 7, 599-606 Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group J. A. Garcia-Rodriguez, J. E. Garcia Sanchez,

More information

Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing

Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Erika Matuschek, Ph D Lead Scientist/Operational Manager EUCAST Development Laboratory (EDL) Växjö, Sweden ASM/ESCMID

More information

Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer

Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer Test Organisms: Staphylococcus aureus (ATCC 6538) Enterobacter aerogenes (ATCC 13048) Pseudomonas aeruginosa (ATCC 15442) Methicillin Resistant

More information

Received 26 April 2000/Returned for modification 21 October 2000/Accepted 26 December 2000

Received 26 April 2000/Returned for modification 21 October 2000/Accepted 26 December 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 927 931 Vol. 45, No. 3 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.3.927 931.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.

More information

2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research. Pharmacological Approaches to Address AR

2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research. Pharmacological Approaches to Address AR 2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research Pharmacological Approaches to Address AR G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 27 July 2000 CPMP/EWP/2655/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER

More information

01/08/2018. Control of Microbial Growth. Methods. Terminology. Disinfectants and Antiseptics. Three approaches. Cleaning. Chemical.

01/08/2018. Control of Microbial Growth. Methods. Terminology. Disinfectants and Antiseptics. Three approaches. Cleaning. Chemical. Control of Microbial Growth Disinfectants and Antiseptics 1 Methods 2 Three approaches Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical elimination Cleaning Filtration

More information

Postantibiotic Effect of,3-lactam Antibiotics on Escherichia coli Evaluated by Bioluminescence Assay of Bacterial ATP

Postantibiotic Effect of,3-lactam Antibiotics on Escherichia coli Evaluated by Bioluminescence Assay of Bacterial ATP ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 199, p. 12-16 Vol. 34, No. 1 66-484/9/112-5$2./ Copyright 199, American Society for Microbiology Postantibiotic Effect of,3-lactam Antibiotics on Escherichia

More information

AN EXAMINATION OF THE EFFECTS OF SIMVASTATIN ON INNATE IMMUNE RESPONSES TO S. AUREUS A RESEARCH PAPER BY TRACI STANKIEWICZ

AN EXAMINATION OF THE EFFECTS OF SIMVASTATIN ON INNATE IMMUNE RESPONSES TO S. AUREUS A RESEARCH PAPER BY TRACI STANKIEWICZ AN EXAMINATION OF THE EFFECTS OF SIMVASTATIN ON INNATE IMMUNE RESPONSES TO S. AUREUS A RESEARCH PAPER BY TRACI STANKIEWICZ SUBMITTED TO THE GRADUATE SCHOOL IN PARTIAL FULFILLMENT OF THE REQUIRMENTS SET

More information

3-lactamases. were commercial preparations. BRL 42715B (sodium salt) was prepared by SmithKline Beecham Pharmaceuticals,

3-lactamases. were commercial preparations. BRL 42715B (sodium salt) was prepared by SmithKline Beecham Pharmaceuticals, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1992, p. 1427-1431 66-484/92/71427-5$2./ Copyright 1992, American Society for Microbiology Vol. 36, No. 7 Simulation of Human Serum Pharmacokinetics of Cefazolin,

More information

Effect of Diuresis on Staphylococcus aureus Kidney

Effect of Diuresis on Staphylococcus aureus Kidney INFECTION AND IMMUNITY, Dec. 1971, p. 74-746 Copyright 1971 American Society for Microbiology Vol. 4, No. 6 Printed in U.S.A. Effect of Diuresis on Staphylococcus aureus Kidney Infections in Mice DOLORES

More information

ASSESSMENT OF THE MICROBICIDAL ACTIVITY OF AN ACCELERATED HYDROGEN PEROXIDE- BASED FORMULATION (AHP-5) AGAINST VRE AND MRSA

ASSESSMENT OF THE MICROBICIDAL ACTIVITY OF AN ACCELERATED HYDROGEN PEROXIDE- BASED FORMULATION (AHP-5) AGAINST VRE AND MRSA Final Report submitted to Virox Technologies Inc. Oakville, Ontario ASSESSMENT OF THE MICROBICIDAL ACTIVITY OF AN ACCELERATED HYDROGEN PEROXIDE- BASED FORMULATION (AHP-5) AGAINST VRE AND MRSA Syed A. Sattar,

More information

M. Ben-David 1, O. Hammer 1, A.Shinderman 1, Y. Gluckman- Yavo 1, M. Fridman 1, D. Gohman 1, G. Ingber 1 and E. Zahavy 2

M. Ben-David 1, O. Hammer 1, A.Shinderman 1, Y. Gluckman- Yavo 1, M. Fridman 1, D. Gohman 1, G. Ingber 1 and E. Zahavy 2 437 Fast Antibiotic Susceptibility Testing Utilizing a Unique Spectral Intensity Ratio Analysis via Single Fluorescence Membrane Dye Staining and Flow Cytometry M. Ben-David 1, O. Hammer 1, A.Shinderman

More information

Use of the Microbial Growth Curve in Postantibiotic Effect Studies of Legionella pneumophila

Use of the Microbial Growth Curve in Postantibiotic Effect Studies of Legionella pneumophila ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2003, p. 1081 1087 Vol. 47, No. 3 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.3.1081 1087.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.

More information

Pharmacodynamics of Metronidazole Determined by a Time-Kill Assay for Trichomonas vaginalis

Pharmacodynamics of Metronidazole Determined by a Time-Kill Assay for Trichomonas vaginalis ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1995, p. 1848 1852 Vol. 39, No. 8 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Pharmacodynamics of Metronidazole Determined by a Time-Kill

More information

Monoclonal antibodies

Monoclonal antibodies Monoclonal antibodies 1. Boost the best-responded mouse 3-5 days before fusion. 2. Build up frozen stock of myeloma cells (NS-1 or P 3 U 1 etc.) in MEM + 10% FCS containing 0.1

More information

Stability of Antibiotics and Chemotherapeutics in

Stability of Antibiotics and Chemotherapeutics in APPUED MICROBIOLOGY, Sept. 1970, p. 447-451 Copyright 1970 American Society for Microbiology Vol. 20, No. 3 Printed in U.S.A. Stability of Antibiotics and Chemotherapeutics in Agar Plates KENNETH J. RYAN,

More information

Polymicrobial Infection in Mice

Polymicrobial Infection in Mice ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1993, P. 1531-1535 0066-4804/93/071531-05$02.00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 7 Use of Cephalosporins for Prophylaxis and

More information

Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model

Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1999, p. 2116 2120 Vol. 43, No. 9 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Characterization and Quantitation

More information

Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection

Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection Acta Pharmacol Sin 2008 Oct; 29 (10): 1253 1260 Full-length article Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection

More information

Essential Science: The State of the Art of Pharmacokinetics and Pharmacodynamics for Antimicrobial Drug Development

Essential Science: The State of the Art of Pharmacokinetics and Pharmacodynamics for Antimicrobial Drug Development Essential Science: The State of the Art of Pharmacokinetics and Pharmacodynamics for Antimicrobial Drug Development 7 September 2018 Nikolas J Onufrak, Pharm.D. Institute for Clinical Pharmacodynamics,

More information

Antifungal PK/PD Made Simple. David Andes, MD University of Wisconsin

Antifungal PK/PD Made Simple. David Andes, MD University of Wisconsin Antifungal PK/PD Made Simple David Andes, MD University of Wisconsin PK/PD Concept Serum Drug Concentration Peak:MIC AUC:MIC Ratio Time Above MIC MIC Time Hypothesis and Concept There is an optimal drug

More information

Chapter 9 Antimicrobial Susceptibility Testing (Agar Disk Diffusion Method)

Chapter 9 Antimicrobial Susceptibility Testing (Agar Disk Diffusion Method) Chapter 9 Antimicrobial Susceptibility Testing (Agar Disk Diffusion Method) The disk diffusion method presented in this chapter has been carefully standardized by the National Committee for Clinical Laboratory

More information

Disk Diffusion Method for Susceptibility Testing of

Disk Diffusion Method for Susceptibility Testing of JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1991, p. 1604-1609 0095-1137/91/081604-06$02.00/0 Copyright 1991, American Society for Microbiology Vol. 29, No. 8 Disk Diffusion Method for Susceptibility Testing

More information

R IC H A R D C. T IL T O N, Ph.D. A N D L IN D A L IE B E R M A N, B.S.

R IC H A R D C. T IL T O N, Ph.D. A N D L IN D A L IE B E R M A N, B.S. A n n a l s o f C l i n i c a l a n d L a b o r a t o r y S c i e n c e, Vol. 4, No. 3 Copyright 1974, Institute for Clinical Science M icrodilution Assay o f Antibiotics in Body Flu ids R IC H A R D C.

More information

10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics

10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical

More information

PSEUDOMONAS-CF-IgG ELISA KIT

PSEUDOMONAS-CF-IgG ELISA KIT PSEUDOMONAS-CF-IgG ELISA KIT PSEUDOMONAS-CF-IgG ELISA Kit is for the quantitative measurement of the antibody level to P. aeruginosa in human serum samples. Application Chronic P. aeruginosa infection

More information

Result:COMPLETE Report Date: December 28 th, 2015

Result:COMPLETE Report Date: December 28 th, 2015 Send to: Clean Water Environmental, LLC 1939 Talamore Court Southeast, Grand Rapids, MI 49546 Dr. Dale Williams Result:COMPLETE Report Date: December 28 th, 2015 Customer Name: Clean Water Environmental,

More information

The general concept of pharmacodynamics

The general concept of pharmacodynamics Asian PK/PD Educational Workshop The general concept of pharmacodynamics modeling the antibacterial effects relations PK / PD This part uses material from presentations of H. Derendorf (Gainesville, Fla.)

More information

Rapid Detection of Bacterial Growth in Blood Cultures by Bioluminescent Assay of Bacterial ATP

Rapid Detection of Bacterial Growth in Blood Cultures by Bioluminescent Assay of Bacterial ATP JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1983, p. 521-525 0095-1137/83/090521-05$02.00/O Copyright C 1983, American Society for Microbiology Vol. 18, No. 3 Rapid Detection of Bacterial Growth in Blood Cultures

More information

Dealer Bulletin. Re: OPTIM 33TB; 3 Minute Fungicidal Claim. OPTIM 33TB Contact Times* To: All Authorized SciCan Dealers Canada

Dealer Bulletin. Re: OPTIM 33TB; 3 Minute Fungicidal Claim. OPTIM 33TB Contact Times*   To: All Authorized SciCan Dealers Canada www.scicancanada.ca Dealer Bulletin To: All Authorized SciCan Dealers Canada Date: June 29, 2017 Re: OPTIM 33TB; 3 Minute Fungicidal Claim Dear SciCan Dealer; OPTIM 33TB has a fungicidal contact time;

More information

MATERIALS AND METHODS

MATERIALS AND METHODS ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1998, p. 2521 2526 Vol. 42, No. 10 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Interaction of Streptococcus

More information

MACROPHAGE KILLING ASSAY

MACROPHAGE KILLING ASSAY MACROPHAGE KILLING ASSAY Updated by: Joseph Chon Date: July 2018 Bowdish Lab, McMaster University Hamilton, ON, Canada www.bowdish.ca BACKGROUND This protocol is used to determine a macrophage population

More information

EM021. Co-Trimoxazole Ezy MIC TM Strip (COT)( mcg/ml) (Trimethoprim/ Sulphamethoxazole) Antimicrobial Susceptibility Testing

EM021. Co-Trimoxazole Ezy MIC TM Strip (COT)( mcg/ml) (Trimethoprim/ Sulphamethoxazole) Antimicrobial Susceptibility Testing Co-Trimoxazole Ezy MIC TM Strip (COT)(0.002-32 mcg/ml) (Trimethoprim/ Sulphamethoxazole) Antimicrobial Susceptibility Testing For In Vitro Diagnostic use EM021 Not for Medicinal Use It is a unique MIC

More information

Efficacy of Peracetic Acid from Perasan MP-2 against non-o157:h7 Pathogenic Escherichia coli

Efficacy of Peracetic Acid from Perasan MP-2 against non-o157:h7 Pathogenic Escherichia coli Efficacy of Peracetic Acid from Perasan MP-2 against non- Pathogenic Escherichia coli Joseph Donabed, B.S. Jonathan Howarth Ph.D Enviro Tech Chemical Services, Modesto, CA November 11, 2011 Background

More information

Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version May 2012

Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version May 2012 Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0 20 May 2012 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised

More information

Received 7 July 2005/Returned for modification 31 October 2005/Accepted 18 June 2006

Received 7 July 2005/Returned for modification 31 October 2005/Accepted 18 June 2006 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2006, p. 2919 2925 Vol. 50, No. 9 0066-4804/06/$08.00 0 doi:10.1128/aac.00859-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Effect

More information

Daptomycin: a new-old antibiotic or how did pharmacodynamics bring back to life a disappointing drug?

Daptomycin: a new-old antibiotic or how did pharmacodynamics bring back to life a disappointing drug? Daptomycin: a new-old antibiotic or how did pharmacodynamics bring back to life a disappointing drug? Unité de Pharmacologie cellulaire et moléculaire F. Van Bambeke Origin of daptomycin Daptomycin is

More information

Pharmacokinetic and Pharmacodynamic Evaluation of Rib-X P-873 versus Klebsiella pneumoniae in a Neutropenic Murine Thigh Infection Model

Pharmacokinetic and Pharmacodynamic Evaluation of Rib-X P-873 versus Klebsiella pneumoniae in a Neutropenic Murine Thigh Infection Model AAC Accepts, published online ahead of print on 28 January 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02170-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5

More information

1. Procedure for Antibiotic susceptibility test by disc diffusion analysis

1. Procedure for Antibiotic susceptibility test by disc diffusion analysis Nanoparticles Functionalized with Ampicillin Destroy Multiple Antibiotic Resistant Isolates of Pseudomonas aeruginosa, Enterobacter aerogenes and Methicillin Resistant Staphylococcus aureus Ashley Brown

More information

Introduction. Results

Introduction. Results E valuation of Inhibitory Data of Essential Oil Constituents Obtained w i t h Different Microbiological Testing Methods A. Pauli and K.-H. Kubeczka Department of Pharmaceutical Biology, University of Hamburg,

More information

Applicant Name Pharmaceutical form Strength Animal species Route of administration

Applicant Name Pharmaceutical form Strength Animal species Route of administration Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, routes of administration, applicant in the Member States 1/11 Member State EU/EEA Applicant

More information

group C /8-hemolytic streptococci, a-hemolytic been exposed to penicillin, on the removal of the drug there follows a variable recovery period during

group C /8-hemolytic streptococci, a-hemolytic been exposed to penicillin, on the removal of the drug there follows a variable recovery period during THE RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN1 By HARRY EAGLE (From the Section on Experimental Therapeutics, National Institutes of Health, U. S. Public Health Service, Bethesda 14, Maryland)

More information

Biocidal Surface Test - Clinell Wipes ~ Project Report Prepared for GAMA Healthcare Ltd ~ Huddersfield Microbiology Services Oct 06

Biocidal Surface Test - Clinell Wipes ~ Project Report Prepared for GAMA Healthcare Ltd ~ Huddersfield Microbiology Services Oct 06 Biocidal Surface Test - Clinell Wipes ~ Project Report Prepared for GAMA Healthcare Ltd ~ Huddersfield Microbiology Services Oct 06 Summary The ability of Clinell wipes to disinfect contaminated steel

More information

Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods

Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1207 1212 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Influence of Test Conditions on Antifungal Time-Kill

More information

Susceptibility Tests

Susceptibility Tests JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1982, p. 213-217 Vol. 16, No. 2 0095-1137/82/080213-05$02.00/0 In Vitro Studies with Cefotaxime: Disk Diffusion Susceptibility Tests SMITH SHADOMY* AND EDWARD L.

More information

Data Sheet. TCR activator / PD-L1 - CHO Recombinant Cell line Cat. #: 60536

Data Sheet. TCR activator / PD-L1 - CHO Recombinant Cell line Cat. #: 60536 Data Sheet TCR activator / PD-L1 - CHO Recombinant Cell line Cat. #: 60536 Product Description Recombinant CHO-K1 cells constitutively expressing human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274, B7

More information

KILL-TIME STUDIES Antimicrobial Activity of Experimental Solutions Using Legionella pneumophila Test Solution: ACS 200 Submitted June 6, 2012

KILL-TIME STUDIES Antimicrobial Activity of Experimental Solutions Using Legionella pneumophila Test Solution: ACS 200 Submitted June 6, 2012 KILL-TIME STUDIES Antimicrobial Activity of Experimental Solutions Using Legionella pneumophila Test Solution: ACS 200 Submitted June 6, 2012 October 11, 2012 PREPARED FOR: Results RNA 1272 South 1380

More information

PASSIVE PROTECTION BY HUMAN SERUM IN MICE INFECTED WITH ENCAPSULATED STAPHYLOCOCCUS A UREUS

PASSIVE PROTECTION BY HUMAN SERUM IN MICE INFECTED WITH ENCAPSULATED STAPHYLOCOCCUS A UREUS PASSIVE PROTECTION BY HUMAN SERUM IN MICE INFECTED WITH ENCAPSULATED STAPHYLOCOCCUS A UREUS K. YOSHIDA, Y. ICHIMAN, S. NARIKAWA, M. TAKAHASHI, E. KONO* AND C. L. SAN CLEMENTE? Department of Microbiology

More information

such a specimen is often difficult t o obtain.

such a specimen is often difficult t o obtain. Assays of Antimicrobial Agents in Serum by Josephine A. Morello, Ph.D. Under certain clinical circumstances, it will be necessary to measure the antibiotic levels in the b l o o d of a patient being given

More information

E. A. EDWARDS' AND G. L. LARSON

E. A. EDWARDS' AND G. L. LARSON APPLIED MICROBIOLOGY, Dec. 1974, p. 972-976 Copyright 0 1975 American Society for Microbiology Vol. 28, No. 6 Printed in U.S.A. New Method of Grouping Beta-Hemolytic Streptococci Directly on Sheep Blood

More information

Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical

Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed

More information

Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents

Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents EUCAST DEFINITIVE DOCUMENT E.Def 1.2 MAY 2000 Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents European Committee forantimicrobial SusceptibilityTesting

More information

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997 Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products

More information

INFLUENCE OF A SUB INHIBITORY CONCENTRATION OF ANTIBIOTICS ON OPSONO-PHAGOCYTIC FUNCTIONS OF KLEBSIELLA PNEUMONIAE BY HUMAN PHAGOCYTES

INFLUENCE OF A SUB INHIBITORY CONCENTRATION OF ANTIBIOTICS ON OPSONO-PHAGOCYTIC FUNCTIONS OF KLEBSIELLA PNEUMONIAE BY HUMAN PHAGOCYTES Influence of sub-mic of antibiotics on phagocytes 1487 INFLUENCE OF A SUB INHIBITORY CONCENTRATION OF ANTIBIOTICS ON OPSONO-PHAGOCYTIC FUNCTIONS OF KLEBSIELLA PNEUMONIAE BY HUMAN PHAGOCYTES YASUO ONO,

More information

Test Method of Specified Requirements of Antibacterial Textiles for Medical Use FTTS-FA-002

Test Method of Specified Requirements of Antibacterial Textiles for Medical Use FTTS-FA-002 Test Method of Specified Requirements of Antibacterial Textiles for Medical Use FTTS-FA-002 FTTS-FA-002 Antibacterial Textiles for Medical Use Antibacterial Textiles suppress and even kill harmful bacteria

More information

6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics

6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical

More information

Lab Three :. Sensitivity test:

Lab Three :. Sensitivity test: Lab Three :. Sensitivity test: Or Diffusion Test: Antibiotic sensitivity test: is a laboratory method for determining the susceptibility of organisms to therapy with antibiotics, Antibiotic susceptibility

More information

4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF. The microbiological assay was performed by using the test

4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF. The microbiological assay was performed by using the test 109 4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF AMOXICILLIN The microbiological assay was performed by using the test organism Staphylococcus aureus. The strain was isolated from soil and allowed

More information

Adaptation of a Bacterial Growth Detection Assay on the VICTOR Nivo Multimode Plate Reader for Measurement of Antibiotic Effects

Adaptation of a Bacterial Growth Detection Assay on the VICTOR Nivo Multimode Plate Reader for Measurement of Antibiotic Effects APPLICATION NOTE Multimode Detection Authors: Maria Kuzikov Dr. Bernhard Ellinger Fraunhofer IME ScreeningPort Hamburg, Germany Adaptation of a Bacterial Growth Detection Assay on the VICTOR Nivo Multimode

More information

Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products

Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products 1 2 3 4 24 September 2015 EMA/CHMP/594085/2015 Committee for Human Medicinal Products (CHMP) 5 6 7 8 Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal

More information

Postantibiotic effects with Bacteroides fragiris determined by viable counts and COz generation

Postantibiotic effects with Bacteroides fragiris determined by viable counts and COz generation ORIGINAL ARTICLE Postantibiotic effects with Bacteroides fragiris determined by viable counts and COz generation IDepartments of Clinical Microbiology, Borgarspitalinn (Reykjavik City Hospital), Reykjavik,

More information

A membrane filter technique for testing disinfectants

A membrane filter technique for testing disinfectants J. clin. Path., 1975, 28, 71-76 A membrane filter technique for testing disinfectants JEAN PRINCE', C. E. A. DEVERILL, AND G. A. J. AYLIFFE From the Hospital Infection Research Laboratory, Birmingham SYNOPSIS

More information

INTRODUCTION Sanitization sterilization Antibiotics Bactericidal Bacteriostatic Antiseptics disinfectants

INTRODUCTION Sanitization sterilization Antibiotics Bactericidal Bacteriostatic Antiseptics disinfectants INTRODUCTION Infectious agents on environmental surfaces, given the correct circumstances, may potentially find their way into an unsuspecting victim. Thus, it is important to keep the surfaces we regularly

More information

In Vitro and In Vivo Antibacterial Activities of the Tricyclic Ketolide. and Its Analogs

In Vitro and In Vivo Antibacterial Activities of the Tricyclic Ketolide. and Its Analogs VOL. 57 NO. 8, AUG. 2004 THE JOURNAL OF ANTIBIOTICS pp. 518-527 In Vitro and In Vivo Antibacterial Activities of the Tricyclic Ketolide TE-802 and Its Analogs TAKEO ONO, MASATO KASHIMURA*, KEIKO SUZUKI,

More information

Technical Performance and Clinical Relevance

Technical Performance and Clinical Relevance CLINICAL MICROBIOLOGY REVIEWS, Oct. 1992, p. 420-432 0893-8512/92/040420-13$02.00/0 Copyright 1992, American Society for Microbiology Vol. 5, No. 4 Tests for Bactericidal Effects of Antimicrobial Agents:

More information